- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept
- Drug
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 71
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 66 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 1,115
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Knee Osteoarthritis
- Interventions
- Whole Body Vibration
- Other
- Lead sponsor
- California State University, Fullerton
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Fullerton, California
- Conditions
- Rheumatoid Arthritis
- Interventions
- Not listed
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,026 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 192
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 170 more
- Conditions
- Sjogrens Syndrome
- Interventions
- Ianalumab (VAY736), Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 612 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 32
- States / cities
- Fullerton, California • La Palma, California • Van Nuys, California + 27 more
- Conditions
- Malignant Neoplasm
- Interventions
- Biospecimen Collection, Questionnaire Administration
- Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 999,999 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1997 – 2033
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Concord, California • Duarte, California + 29 more
- Conditions
- Pancreatic Cancer
- Interventions
- Pegilodecakin, FOLFOX
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 57
- States / cities
- Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 49 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, Enzalutamide, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 28
- States / cities
- Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more
- Conditions
- Primary Sjogrens Disease
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 42
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 36 more
- Conditions
- Relapsing Multiple Sclerosis (RMS)
- Interventions
- Ofatumumab approved dose, Ofatumumab new dose
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 50 more
- Conditions
- Advanced Solid Tumor, Colorectal Cancer
- Interventions
- TORL-3-600
- Drug
- Lead sponsor
- TORL Biotherapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Fullerton, California • Los Angeles, California • Denver, Colorado + 4 more
- Conditions
- COVID-19
- Interventions
- PBI-0451 (Pomotrelvir), Placebo
- Drug
- Lead sponsor
- Pardes Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 54
- States / cities
- Mesa, Arizona • Bakersfield, California • Canoga Park, California + 41 more
- Conditions
- Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Second-line Treatment, VEGF
- Interventions
- TKI258
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Fullerton, California • Los Angeles, California + 15 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil, Cisplatin
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 49
- States / cities
- Chandler, Arizona • Tucson, Arizona • Fullerton, California + 43 more
- Conditions
- Autoimmunity, Inflammation
- Interventions
- Secukinumab s.c. injection
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 100 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 28
- States / cities
- Fullerton, California • La Mesa, California • San Leandro, California + 25 more
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
- Interventions
- Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil, Oxaliplatin, Zolbetuximab, Leucovorin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 81 more
- Conditions
- Breast Cancer
- Interventions
- Docetaxel, Trastuzumab, Carboplatin, Bevacizumab, 5-Fluorouracil, Epirubicin, Cyclophosphamide
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3,509 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 393
- States / cities
- Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 272 more
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
- Interventions
- PF-08634404, Sigvotatug Vedotin, PF-08046054/SGN-PDL1V
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 55
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 29 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tocilizumab 162 mg, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 44
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Ovarian Neoplasms
- Interventions
- AMG 479
- Biological
- Lead sponsor
- Translational Research in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 16
- States / cities
- Bakersfield, California • Fullerton, California • La Verne, California + 10 more
- Conditions
- Acne Vulgaris
- Interventions
- FMX-101, 4% minocycline foam, Vehicle Foam
- Drug
- Lead sponsor
- Vyne Therapeutics Inc.
- Industry
- Eligibility
- 9 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Fremont, California • Fullerton, California + 25 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- Faster-acting insulin aspart, insulin aspart, insulin degludec
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 57
- States / cities
- Tucson, Arizona • Concord, California • Encino, California + 49 more
- Conditions
- Chronic Myelogenous Leukemia - Chronic Phase
- Interventions
- asciminib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 71 more
- Conditions
- Follicular Lymphoma
- Interventions
- Rituximab, Lenalidomide, Rituximab-CHOP, Rituximab-CVP, Rituximab-Bendamustine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 26
- States / cities
- Chandler, Arizona • Fullerton, California • Los Angeles, California + 21 more
- Conditions
- MET Positive, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Rilotumumab
- Drug · Other · Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 627
- States / cities
- Jonesboro, Arkansas • Little Rock, Arkansas • Anaheim, California + 402 more